Mirtazapine Bluefish (Mirtazapine)

• Mirtazapine is a NaSSA antidepressant that acts on multiple neurotransmitter systems and is used primarily in the treatment of depressive disorders.
• Major depressive disorder: reduces depressive symptoms and improves overall functioning.
• Treatment‑resistant depression: may be considered when first‑line agents have failed.
• Depressive symptoms with insomnia: provides a sedative effect that can improve sleep quality.
• Adjunct therapy in bipolar depression: may be added to mood stabilizers to address the depressive phase.
• Anxiety co‑morbid with depression: can alleviate anxiety symptoms.

• Mirtazapine antagonizes central presynaptic α2‑adrenergic receptors, which disinhibits norepinephrine release, and blocks 5‑HT2 and 5‑HT3 serotonin receptors, enhancing serotonergic transmission through 5‑HT1 receptors. It also acts as a potent H1 histamine receptor antagonist, contributing to its sedative and appetite‑stimulating effects. By modulating these pathways, mirtazapine restores balance in mood‑regulating circuits and improves clinical symptoms in depressed patients.

Mirtazapine may cause a range of adverse reactions, which are generally categorized by frequency.

Common Side Effects

• Sedation: feeling unusually sleepy or drowsy.
• Increased appetite: heightened desire for food, often leading to weight gain.
• Weight gain: noticeable increase in body weight over time.
• Dry mouth: reduced salivation causing oral discomfort.

Serious or Rare Side Effects

• Agranulocytosis: severe reduction in white blood cells requiring immediate medical attention.
• Severe hypersensitivity: rash, swelling, or difficulty breathing indicating an allergic reaction.
• Suicidal thoughts: emergence or worsening of suicidal ideation, especially early in treatment.

Before initiating mirtazapine therapy, clinicians should evaluate several safety considerations.

• Assess hepatic function: adjust use in patients with liver impairment.
• Monitor mood changes: watch for worsening depression or emergence of suicidal thoughts.
• Caution in cardiovascular disease: be aware of potential orthostatic hypotension.
• Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms.
• Use cautiously in elderly: increased risk of sedation and falls.
• Check renal function: dose may need adjustment in severe renal impairment.
• Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with several medications, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): concurrent use can cause hypertensive crisis or serotonin syndrome.
• CYP3A4 strong inhibitors (e.g., ketoconazole, itraconazole): may raise mirtazapine plasma concentrations, increasing toxicity risk.
• Central nervous system depressants (e.g., alcohol, benzodiazepines): additive sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• Selective serotonin reuptake inhibitors (SSRIs): combined use may increase risk of serotonin syndrome; monitor symptoms.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower mirtazapine levels, reducing effectiveness.
• Antihistamines: additive sedative effect may be enhanced; adjust dose if needed.